Published in PLoS One on August 29, 2014
Improved methods of AAV-mediated gene targeting for human cell lines using ribosome-skipping 2A peptide. Nucleic Acids Res (2015) 0.76
Recombinant adeno-associated virus vectors in the treatment of rare diseases. Expert Opin Orphan Drugs (2015) 0.75
Optimization of adeno-associated virus vector-mediated gene transfer to the respiratory tract. Gene Ther (2017) 0.75
Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter. J Mol Appl Genet (1982) 54.79
A human beta-actin expression vector system directs high-level accumulation of antisense transcripts. Proc Natl Acad Sci U S A (1987) 6.36
Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther (2008) 5.83
Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science (2009) 5.31
Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science (2011) 5.04
Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell (1993) 4.04
Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood (2005) 3.71
Homologous integration in mammalian cells without target gene selection. Genes Dev (1988) 3.54
Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev (2008) 3.30
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest (2010) 3.11
Human gene targeting by viral vectors. Nat Genet (1998) 3.02
Powerful and versatile enhancer-promoter unit for mammalian expression vectors. Gene (1986) 3.01
The variability in activity of the universally expressed human cytomegalovirus immediate early gene 1 enhancer/promoter in transgenic mice. Nucleic Acids Res (1991) 2.93
The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. Science (1993) 2.77
Targeted transgene insertion into human chromosomes by adeno-associated virus vectors. Nat Biotechnol (2002) 2.73
Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther (2008) 2.54
The AAV vector toolkit: poised at the clinical crossroads. Mol Ther (2012) 2.53
Genetic knockouts and knockins in human somatic cells. Nat Protoc (2007) 2.21
Ku regulates the non-homologous end joining pathway choice of DNA double-strand break repair in human somatic cells. PLoS Genet (2010) 2.14
Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells. Proc Natl Acad Sci U S A (2011) 2.12
Systematic comparison of constitutive promoters and the doxycycline-inducible promoter. PLoS One (2010) 2.08
Genetic fate of recombinant adeno-associated virus vector genomes in muscle. J Virol (2003) 2.07
Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proc Natl Acad Sci U S A (2009) 2.02
How I treat paroxysmal nocturnal hemoglobinuria. Blood (2009) 1.97
Transient and stable transgene expression in human embryonic stem cells. Stem Cells (2007) 1.91
Increased persistence of lung gene expression using plasmids containing the ubiquitin C or elongation factor 1alpha promoter. Gene Ther (2001) 1.72
Analysis of transduction efficiency, tropism and axonal transport of AAV serotypes 1, 2, 5, 6, 8 and 9 in the mouse brain. PLoS One (2013) 1.70
Efficiency of recombination by Cre transient expression in embryonic stem cells: comparison of various promoters. J Biochem (1997) 1.68
Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras mediated transformation. Cancer Res (2007) 1.63
Positive genetic selection for gene disruption in mammalian cells by homologous recombination. Proc Natl Acad Sci U S A (1989) 1.50
Intracellular transport of recombinant adeno-associated virus vectors. Gene Ther (2012) 1.44
Comparison of the EF-1 alpha and the CMV promoter for engineering stable tumor cell lines using recombinant adeno-associated virus. Anticancer Res (2003) 1.35
Expression of human beta-interferon cDNA under the control of a thymidine kinase promoter from herpes simplex virus. Nature (1982) 1.32
Stable expression of hrGFP by mouse embryonic stem cells: promoter activity in the undifferentiated state and during dopaminergic neural differentiation. Stem Cells (2003) 1.30
A comparison of exogenous promoter activity at the ROSA26 locus using a ΦiC31 integrase mediated cassette exchange approach in mouse ES cells. PLoS One (2011) 1.29
Deletion of PTEN promotes tumorigenic signaling, resistance to anoikis, and altered response to chemotherapeutic agents in human mammary epithelial cells. Cancer Res (2009) 1.29
Cdk2 is required for p53-independent G2/M checkpoint control. PLoS Genet (2010) 1.21
Use of the human EF-1alpha promoter for expression can significantly increase success in establishing stable cell lines with consistent expression: a study using the tetracycline-inducible system in human cancer cells. Nucleic Acids Res (1999) 1.17
Quantitative comparison of constitutive promoters in human ES cells. PLoS One (2010) 1.08
Adenovirus-mediated transfer of p53 and p16(INK4a) results in pancreatic cancer regression in vitro and in vivo. Gene Ther (2001) 1.04
A syngeneic variance library for functional annotation of human variation: application to BRCA2. Cancer Res (2008) 1.02
The human pre-B cell line Nalm-6 is highly proficient in gene targeting by homologous recombination. DNA Cell Biol (2006) 1.01
Effects of adenovirus-mediated p16INK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells. Oncogene (1998) 1.00
Strong transcriptional promoter in the 5' upstream region of the human beta-actin gene. Gene (1988) 0.98
An efficient expression vector for stable expression in human liver cells. Gene (1993) 0.89
Long-term expression of a T-cell receptor beta-chain gene in mice reconstituted with retrovirus-infected hematopoietic stem cells. Proc Natl Acad Sci U S A (1990) 0.88
Adenoviral vector containing wild-type p16 suppresses prostate cancer growth and prolongs survival by inducing cell senescence. Cancer Gene Ther (2000) 0.87
Strong, long-term transgene expression in rat liver using chicken beta-actin promoter associated with cytomegalovirus immediate-early enhancer (CAG promoter). Cell Transplant (2000) 0.87
Comparisons of tumor suppressor p53, p21, and p16 gene therapy effects on glioblastoma tumorigenicity in situ. Biochem Biophys Res Commun (2001) 0.85
Optimization of adenovirus serotype 35 vectors for efficient transduction in human hematopoietic progenitors: comparison of promoter activities. Gene Ther (2005) 0.83
Persistent expression of foreign genes in cultured hepatocytes: expression vectors. Gene (1999) 0.83
Promoter dependence of transgene expression by lentivirus-transduced human blood-derived endothelial progenitor cells. Stem Cells (2005) 0.83
PMA induces expression from the herpes simplex virus thymidine kinase promoter via the activation of JNK and ERK in the presence of adenoviral E1A proteins. Arch Biochem Biophys (2009) 0.80
Growth inhibition of human cancer cells by 5-aza-2'-deoxycytidine does not correlate with its effects on INK4a/ARF expression or initial promoter methylation status. Mol Cancer Ther (2009) 0.80
Assessment of the long-term transcriptional activity of a 550-bp-long human β-actin promoter region. Plasmid (2012) 0.79
Simple monitoring of gene targeting efficiency in human somatic cell lines using the PIGA gene. PLoS One (2012) 0.79
Comparison of the expression of a mutant dihydrofolate reductase under control of different internal promoters in retroviral vectors. Hum Gene Ther (1992) 0.79
p16 gene therapy: a potentially efficacious modality for nasopharyngeal carcinoma. Mol Cancer Ther (2003) 0.78
A system for the measurement of gene targeting efficiency in human cell lines using an antibiotic resistance-GFP fusion gene. Biotechniques (2012) 0.78
Stable expression of human tissue-type plasminogen activator regulated by beta-actin promoter in three human cell lines: HeLa, WI-38 VA13 and KMS-5. Biochim Biophys Acta (1991) 0.78
Constitutive high-level production of human lymphotoxin by CHO-K1 cells transformed with the human lymphotoxin gene controlled by a human beta-actin promoter. Agric Biol Chem (1991) 0.77